Idera Pharmaceuticals, Inc.
IDRA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 100% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -3,894.7% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -5,839.6% |
| EPS Diluted | -7.18 | 31.55 | -56.63 | -33.66 |
| % Growth | -122.8% | 155.7% | -68.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |